Insider trading

Period: 120 months Stock: GNLX Type of trade: Bought × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

10 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

10 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

10 decisions over 120 months Remove this filter
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

10 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
10 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
10 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

10 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
29 May 2024
Tyree James L Director
Bought
no price 6,250 shares
181%
First buy on file
29 May 2024
Smither John W Director
Bought
no price 6,250 shares
90.3%
First buy on file
29 May 2024
Thomas John Director
Bought
no price 2,500 shares
0.5%
First buy on file
29 May 2024
Mirabelli Mary Director
Bought
no price 8,000 shares
179%
First buy on file
29 May 2024
Yu Yong VP, Clinical Trial Operations
Bought
no price 2,500 shares
opened
First buy on file
29 May 2024
Zindrick Thomas President and CEO · indirect
Bought
no price 200,000 shares
opened
First buy on file
29 May 2024
Smalling Ralph Head of Regulatory
Bought
no price 1,250 shares
10.4%
First buy on file
29 May 2024
Ryder Sean General Counsel
Bought
no price 10,000 shares
×17
First buy on file
29 May 2024
Zak Lourie S. Chief Financial Officer
Bought
no price 31,250 shares
opened
First buy on file
26 Jan 2023
Zhang Qian Associate VP, Research · indirect
Bought
$1.25K 200 at 6.25
opened
First buy on file
Showing 1–10 of 10.